MedTrace Logo

Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure

NCT01858480 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-07-14

No results posted yet for this study

Summary

To evaluate the safety and to determine the efficacy of D-ribose for the treatment of congestive heart failure (CHF) in subjects who have been stabilized following hospitalization with acute decompensation.

Conditions

  • Congestive Heart Failure

Interventions

DRUG

D-ribose

D-ribose powder for oral solution and D-ribose for injection.

OTHER

Placebo

Placebo dosage form designed to mock active.

Sponsors & Collaborators

  • RiboCor, Inc.

    lead INDUSTRY

Principal Investigators

  • Wilson S Colucci, MD · Boston University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01858480 on ClinicalTrials.gov